Literature DB >> 2272879

Sympathetic activation in dogs with congestive heart failure caused by chronic mitral valve disease and dilated cardiomyopathy.

W A Ware1, D D Lund, A R Subieta, P G Schmid.   

Abstract

Baseline plasma norepinephrine (NE) and epinephrine (EPI) concentrations were measured in dogs with naturally acquired heart failure (HF) caused by either degenerative mitral valve disease and mitral regurgitation (MR) or idiopathic dilated cardiomyopathy (DCM). Compared with controls (clinically normal), dogs with HF had increased plasma NE concentration, which was correlated positively with clinical severity of HF. Dogs with the most severe degree of HF (New York Heart Association functional class IV) had mean NE concentration significantly (P less than 0.05) greater than that of dogs with all other functional classes of HF. Overall, mean NE concentration in dogs with DCM was greater than that in dogs with MR. Plasma EPI concentration was not different between control dogs and dogs with HF or between dogs with DCM or MR. Correlations were not found between the echocardiographically derived end systolic volume index (used as an estimate of myocardial function) and plasma NE and EPI concentrations or serum sodium or potassium concentration. Dogs with DCM, as a group, had a small but significant (P less than 0.05) decrease in serum sodium concentration, compared with dogs with MR. This difference was maintained only for class-IV HF when dogs were separated according to functional HF class. In dogs with DCM, significant inverse correlation was found between plasma NE and serum sodium concentrations. When grouped together, all dogs with HF maintained this relationship; however, dogs with MR did not have correlation between plasma NE and serum sodium concentrations. Plasma EPI and serum sodium concentrations were not correlated for any group. It was concluded that in dogs, plasma NE, but not EPI, concentration is high in relation to the clinical severity of naturally acquired HF.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2272879

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  7 in total

1.  Sildenafil improves heart rate variability in dogs with asymptomatic myxomatous mitral valve degeneration.

Authors:  Prapawadee Pirintr; Nakkawee Saengklub; Vudhiporn Limprasutr; Suwanakiet Sawangkoon; Anusak Kijtawornrat
Journal:  J Vet Med Sci       Date:  2017-07-17       Impact factor: 1.267

2.  Long-term effect of sildenafil on echocardiographic parameters in dogs with asymptomatic myxomatous mitral valve degeneration.

Authors:  Anusak Kijtawornrat; Siripen Komolvanich; Nakkawee Saengklub; Prapawadee Pirintr; Pakit Boonpala; Chollada Buranakarl
Journal:  J Vet Med Sci       Date:  2017-03-11       Impact factor: 1.267

3.  Polymorphisms in the serotonin transporter gene and circulating concentrations of neurotransmitters in Cavalier King Charles Spaniels with myxomatous mitral valve disease.

Authors:  Maria J Reimann; Merete Fredholm; Signe E Cremer; Liselotte B Christiansen; Kathryn M Meurs; Jacob E Møller; Jens Häggström; Jens Lykkesfeldt; Lisbeth H Olsen
Journal:  J Vet Intern Med       Date:  2021-10-02       Impact factor: 3.333

4.  Short-term follow-up of exercise training program and beta-blocker treatment on quality of life in dogs with naturally acquired chronic mitral valve disease.

Authors:  M Marcondes-Santos; A P Mansur; F S Fragata; C M C Strunz
Journal:  Braz J Med Biol Res       Date:  2015-08-04       Impact factor: 2.590

5.  Quality of Life Score as a Predictor of Death in Dogs with Degenerative Mitral Valve Disease.

Authors:  Célia M C Strunz; Mário Marcondes-Santos; Julio Yoshio Takada; Fernanda S Fragata; Antônio de Pádua Mansur
Journal:  Arq Bras Cardiol       Date:  2017-03-30       Impact factor: 2.000

6.  Temporal changes in clinical and radiographic variables in dogs with preclinical myxomatous mitral valve disease: The EPIC study.

Authors:  Adrian Boswood; Sonya G Gordon; Jens Häggström; Martin Vanselow; Gerhard Wess; Rebecca L Stepien; Mark A Oyama; Bruce W Keene; John Bonagura; Kristin A MacDonald; Mark Patteson; Sarah Smith; Philip R Fox; Karen Sanderson; Richard Woolley; Viktor Szatmári; Pierre Menaut; Whitney M Church; M Lynne O'Sullivan; Jean-Philippe Jaudon; Jan-Gerd Kresken; John Rush; Kirstie A Barrett; Steven L Rosenthal; Ashley B Saunders; Ingrid Ljungvall; Michael Deinert; Eric Bomassi; Amara H Estrada; Maria J Fernandez Del Palacio; N Sydney Moise; Jonathan A Abbott; Yoko Fujii; Alan Spier; Michael W Luethy; Roberto A Santilli; Masami Uechi; Anna Tidholm; Christoph Schummer; Philip Watson
Journal:  J Vet Intern Med       Date:  2020-03-22       Impact factor: 3.333

7.  The chromogranin A-derived peptides catestatin and vasostatin in dogs with myxomatous mitral valve disease.

Authors:  Katja Höglund; Jens Häggström; Odd Viking Höglund; Mats Stridsberg; Anna Tidholm; Ingrid Ljungvall
Journal:  Acta Vet Scand       Date:  2020-08-05       Impact factor: 1.695

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.